From: Childhood Acute Myeloid Leukemia Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 3. Lineage Assignment Criteria for Mixed-Phenotype Acute Leukemia According to the 5th Edition (2022) of the World Health Organization Classification of Hematolymphoid Tumorsa
| Lineage | Criterion |
|---|---|
| B lineage | |
| CD19 strongb, OR | 1 or more also strongly expressed: CD10, CD22, or CD79ad |
| CD19 weakc | 2 or more also strongly expressed: CD10, CD22, or CD79ad |
| T lineage | |
| CD3 (cytoplasmic or surface)e | Intensity in part exceeds 50% of mature T-cells level by flow cytometry or immunocytochemistry positive with non-zeta chain reagent |
| Myeloid lineage | |
| Myeloperoxidase, OR | Intensity in part exceeds 50% of mature neutrophil level |
| Monocytic differentiation | 2 or more expressed: Nonspecific esterase, CD11c, CD14, CD64, or lysozyme |
aCredit: Khoury, J.D., Solary, E., Abla, O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36, 1703–1719 (2022). https://doi
.org/10.1038 /s41375-022-01613-1.[13] This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. bCD19 intensity in part exceeds 50% of normal B cell progenitor by flow cytometry.
cCD19 intensity does not exceed 50% of normal B cell progenitor by flow cytometry.
dProvided T lineage not under consideration, otherwise cannot use CD79a.
eUsing anti-CD3 epsilon chain antibody.